feed rss
Star Alliance

Preliminary Scientific Programme




The link between disasters and Nephrology
Mehmet Sukru Sever, Istanbul, Turkey


Innate immunity: from flies to humans
Jules A. Hoffmann, Strasbourg, France

Will it one day be possible to engineer a complete kidney? Problems and perspectives
Giuseppe Remuzzi, Bergamo, Italy

Improving outcome of patients with CKD: diets and enteral supplements
T. Alp Ikizler, Nashville, USA


  MAY 18, 2013 


In order to participate in the CME Courses held on May 18, 2013, all regularly registered congress members must go to the session halls and have their badge scanned by the hostesses at the entrance (at participant’s own responsibility). Please note that the seat capacity of the conference rooms is limited, therefore participation in these courses will be on a “first come first served” basis. The courses are reserved to regularly registered congress members and are included in the registration fee.

1. EURECA-m (EUropean REnal CArdiovascular Medicine) Working Group


CME 1.1
Critical reappraisal of cardiovascular end-organ damages in ESRD
- The importance of assessing lung congestion in patients  with heart disease
Luna Gargani, Pisa, Italy
- Arterial and valvular disorders: pathophysiology and clinical manifestations
Adrian Covic, Iasi, Romania
- Pathophysiology of left ventricular hypertrophy and dysfunction in CKD
Danilo Fliser, Homburg/Saar, Germany


CME 1.2
Interplay of inflammation and CKD-MBD in vascular injury
- Epidemiology linking inflammation and CKD-MBD
Juan-Jesus Carrero-Roig, Stockholm, Sweden
- Inflammation, CKD-MBD and endothelial dysfunction
Mahmut Ilker Yilmaz, Ankara, Turkey
- Kidney inflammation and CKD-MBD regulatory molecules
Alberto Ortiz, Madrid, Spain


CME 1.3
Reverse cardiovascular epidemiology in CKD patients
- Blood pressure variability: does it matter and how to assess it?
Francesca Mallamaci, Reggio Calabria, Italy
- BMI and lipids: should we prefer obesity or wasting?
Denis Fouque, Lyon, France
- Atherosclerosis vs. calcification and their impact on cardiovascular outcome in CKD patients
Gunnar Heine, Homburg/Saar, Germany


CME 1.4
Renal denervation for treatment of severe hypertension
- Rationale for renal denervation
Peter Blankestijn, Utrecht, the Netherlands
- Screening / selection of patients and follow-up
Andrzej Wiecek, Katowice, Poland
- First results and technical aspects
Felix Mahfoud, Homburg/Saar, Germany
- Present research activity: databases / studies etc. in renal denervation
Peter Blankestijn, Utrecht, the Netherlands and Andrzej Wiecek, Katowice, Poland
2. Immunonephrology Working Group


CME 2.1
Renal Pathology course in collaboration with the International Renal Pathology Society Renal interstitial inflammation: more important than glomerular injury?
- Renal interstitial inflammation: chicken or egg?
Meguid El-Nahas, Sheffield, UK
- Interstitial inflammation in human lupus nephritis
Anthony Chang, Chicago, USA
- Interstitial inflammation in IgA nephropathy
Loreto Gesualdo, Bari, Italy
- Karyomegalic interstitial nephropathy: from genetic defect of DNA damage repair to progression of kidney disease
Pierre Ronco, Paris, France

CME 2.2
Treatment of Lupus Nephritis
- Rituximab (in the treatment of lupus nephritis): do the benefits outweight the risks?
Vladimir Tesar, Prague, Czech Republic
- Rituximab associated with mycophenolate: the LUNAR trial experience
Fernando Fervenza, Rochester, USA
- Update on biologic and stem cell therapies for lupus nephritis
David Jayne, Cambridge, UK
- The role of repeated biopsies in the of Lupus Nephritis
Franco Ferrario, Milan, Italy

CME 2.3
Diseases of podocytes: basic research and clinical value
- Podocytes: a gateway to new biology and diagnostics
Harry Holthöfer, Dublin, Ireland
- The role of the parietal epithelial cell versus the podocyte in glomerular disease
Jürgen Floege, Aachen, Germany
- The angiotensin signalling in the podocyte and implications for therapy
Ariela Benigni, Bergamo, Italy
- Parietal epithelial cell activation marker in early recurrence of FSGS in the transplant
Agnes Fogo, Nashville, USA

CME 2.4
Complement dysregulation and renal diseases
- Update in complement involvement in renal diseases
Mohamed Daha, Leiden, the Netherlands
- aHUS: a happy end story from CFH mutations to cure
Marina Noris, Bergamo, Italy
- Dense Deposit Disease and C3GN: different diseases or parts of a spectrum?
Daniel Gale, London, UK
- Genetics of complement in aHUS
Santiago Rodriguez de Cordoba, Madrid, Spain


3. EuDial (European Dialysis) Working Group

CME 3.1
Basics for delivering safe and effective HDF
- Haemodiafiltration: basic principles and different choices
Claudio Ronco, Vicenza, Italy
- On-line preparation of fluid for convective therapy in theory and practice
Ingrid Ledebo, Lund, Sweden
- Quality assurance from organizational structure to continuous quality improvement strategies

Richard Ward, Louisville, USA
- Regulations governing clinical use of HDF in Europe
Alain Ragon, Marseille, France

CME 3.2
HDF in children
- Feasibility and practical aspects of performing HDF in the young
Michel Fischbach, Strasbourg, France
- Management and benefits of CVVHDF in the paediatric intensive care
Aysun Karabay Bayazit, Adana, Turkey
- Is there a role for HDF in intensified dialysis regimens?
Dominik Müller, Berlin, Germany
- Advantages of HDF over conventional HD in children
Rukshana Shroff, London, UK

CME 3.3
HDF in today’s clinical practice
- Haemodiafiltration: dosing, treatment targets and troubles
Menso Nubé, Amsterdam, the Netherlands
- Loss of nutrients or other compounds during HDF: parenteral nutrition, drug dosing and anticoagulation
Fatih Kircelli, Istanbul, Turkey
- HDF in short daily and long nocturnal treatment schemes
Francisco Maduell, Barcelona, Spain
- Discussion on present status of knowledge with respect of effect on clinical outcome and future initiatives. Role of EuDial 
Peter Blankestijn, Utrecht, the Netherlands
4. EUTox

CME 4.1
a) i. Urinary proteins/peptides as early biomarkers for CKD
Justyna Siwy, Hanover, Germany
a) ii. Overview on the biomarkers approach in CKD or larger
Harald Mischak, Hanover, Germany
b) i. Extracellular calcium regulates serum FGF23 levels
Maria Encarnacion Rodriguez Ortiz, Cordoba, Spain
b) ii. Overview on the biomarkers to assess MBD CKD
Mariano Rodriguez-Portillo, Cordoba, Spain

CME 4.2
Calcium and MBD in CKD
a) i. Clinical cases of CKD MBD
Saimir Seferi, Tirana, Albania
a) ii. Clinical overview of BMD CKD
Goce Spasovski, Skopje, F.Y.R. of Macedonia
b) i. Data on aortic ring calcification
Silvia Salem, Berlin, Germany
b) ii. Mechanisms of Ca deposition and treatment
Joachim Jankovski, Berlin, Germany

CME 4.3
Endothelium and cardiovascular diseases
a) i. Recent data on endothelium and thrombosis
Bertrand Gondouin, Marseille, France
a) ii. Endothelium, the good; chronic kidney diseases, the bad; and cardiovacular diseases, the ugly: a point of view
Stephane Burtey, Marseille, France
b) i. Effects of phosphate on vascular function – New insights
Isabelle Six, Amiens, France
b) ii. Features of CVD in CKD
Ziad Massy, Amiens, France

CME 4.4
Uraemic toxins
a) i. Data on eGFR and uraemic toxin concentration
Nathalie Neirynck, Ghent, Belgium
a) ii. Overview on pathways of renal excretion of uraemic toxins
Griet Glorieux, Ghent, Belgium
b) i. The encyclopaedic update of uraemic toxins data base
Flore Duranton, Montpellier, France
b) ii. Overview on uraemic toxins removal
Angel Argiles, Montpellier, France
5. WGIKD (Working Group on Inherited Kidney Disorders)

CME 5.1
Genetics – New perspectives
- Implications and limitations of genetic approaches to common kidney diseases
Murielle Bochud, Lausanne, Switzerland
- Multigenic pathways: cystic kidney diseases
Carsten Bergmann, Ingelheim, Germany
- GWAS: A new tool to understand renal physiology?
Olivier Devuyst, Zurich, Switzerland

CME 5.2     
Update on tubular disorders
- Disorders of phosphate handling
Carsten Wagner, Zurich, Switzerland
- Update on the physiopathology and treatment of cystinosis
Francesco Emma, Rome, Italy
- Uromodulin-associated kidney diseases
Luca Rampoldi, Milan, Italy

CME 5.3
Autosomal dominant polycystic kidney disease (ADPKD)
- ADPKD: understanding how cysts form
Albert Ong, Sheffield, UK
- ADPKD, markers for progression
Ron T. Gansevoort, Groningen, the Netherlands
- Update on treatment
Vicente Torres, Rochester, USA

CME 5.4
Registries and policies
- EuroCYST and other initiatives in ADPKD
Andreas Serra, Zurich, Switzerland
- The UK Cystinosis Registry
William Van’t Hoff, London, UK
- Therapy of Alport syndrome - Insights from the European Alport Registry
Oliver Gross, Göttingen, Germany


6. CKD/MBD Working Group

CME 6.1
Welcome and introduction
Mario Cozzolino, Milan Italy
1) Calciphylaxis update 2013
- Update in calciphylaxis
Pablo Urena Torres, Paris, France
- Initiation of a pan-european calciphylaxis registry
Vincent Brandenburg, Aachen, Germany
2) CKD-MBD WG initiatives
- Survey on CKD-MBD 2013 initiatives: clinical trial on optimal treatment in CKD
Marc Vervloet, Amsterdam, the Netherlands
- P additives in CKD
Markus Ketteler, Coburg, Germany
- EVOLVE - The end of the beginning or the beginning of the end?
David Goldsmith, London, UK
- Closing remarks
Mario Cozzolino, Milan Italy 


7. ERA-EDTA-ESPN Paediatric Nephrology Track

CME 7.1
Urinary tract infections in children and adults
- Antibiotic treatment for UTI in children: results from a systemic review
Kjell Tullus, London, UK
- Acute pyelonephrits in children

Giovanni Montini, Bologna, Italy
- Follow-up in adult life of children with UTI
Sverker Hansson, Gothenburg, Sweden
- Acute pyelonephritis in adults
Cristiana Rollino, Turin, Italy

CME 7.2
Acute renal failure in the paediatric age group: treatment and outcome
- Early diagnosis of acute renal failure in children
Johan Van de Walle, Ghent, Belgium
- Fluid overload control: drugs and dialysis choices
Etienne Javouhey, Lyon, France
- Early dialysis treatments: how early it should be
Stefano Picca, Rome, Italy
- Epidemiology and outcome of AKI in children
Oguz Soylemezoglu, Ankara, Turkey

CME 7.3
Diagnosis and management of ostoeodystrophy in children with CKD
- The best practice to allow children with ESRD to attain normal final height
Amira Peco Antic, Belgrade, Serbia
- Skeletal disorders and osteodystrophy in children with CKD/ESRD
Dieter Haffner, Hannover, Germany
- Control of hyperphosphatemia
Sevcan A. Bakkaloglu, Ankara, Turkey
- Hyperparathyroidism refractory to treatment: paratiroidectomy
Velibor Tasic, F.Y.R. of Macedonia

CME 7.4
- Nutrition in children with ESRD
Marjolein Bonthuis, Amsterdam, the Netherlands
- Graft loss in children with a kidney transplant
Franz Schaefer, Heidelberg, Germany
- Henoch Schönlein purpura nephritis and IgAN: differences between children and adults
J.C. Davin, Amsterdam, the Netherlands


8. Transplantation Working Group in collaboration with ESOT

CME 8.1
Transplantation in children
- Selection of the deceased donor: who cannot be accepted?
Pierre Cochat, Lyon, France
- Recurrent disease after paediatric kidney transplantation
Patrick Niaudet, Paris, France
- Living donors for children
Anna Bjerre, Oslo, Norway

CME 8.2
How to increase the renal transplant activity in Europe
- Update on ethical issues in living unrelated transplantation: Istanbul Declaration and beyond
Francis L. Delmonico, Boston, USA
- Inequality of access to paediatric kidney transplantation in Europe
Jérôme Harambat, Bordeaux, France
- Improving deceased organ donation - the Croatian experience
Mirela Busic, Zagreb, Croatia
- Machine perfusion: state of the art
Ina Jochmans, Leuven, Belgium
- How to improve the rates of living donation
Willem Weimar, Rotterdam, the Netherlands
- Inclusion and exclusion criteria in the waiting list: the ERBP
Julio Pascual, Barcelona, Spain

CME 8.3
How to improve long term graft function
- Risk factors and long-term consequences of proteinuria in renal transplantation
Jean-Michel Halimi, Tours, France
- Care of the long-term transplant complications: the oncogenic risk. Should we screen for cancer after kidney transplantation?
Josep M. Campistol, Barcelona, Spain
- Does RAS blockade improve outcomes after kidney transplantation?
Armando Torres, La Laguna, Spain
- Optimization of organ donation to improve long term outcome
Francis L. Delmonico, Boston, USA

CME 8.4
Problematic patients in transplantation list: planning the strategy
- Transplanting patients suffering from recurrent/ resistant FSGS: the ERBP
Tim Ulinski, Paris, France
- Transplantation in atypical HUS (haemolytic uremic syndrome)
Chantal Loirat, Paris, France
- Transplantation in the elderly patient
Hans De Fijter, Leiden, the Netherlands
- Transplantation in an infant with CKD: when to plan it
Christer Holmberg, Helsinki, Finland

9. ERA-EDTA Registry

CME 9.1
CKD cohorts across Europe
- Chronic Kidney Disease in Europe
Katharina Lombard-Brück, Amsterdam, the Netherlands
- German CKD study
Kai-Uwe Eckardt, Erlangen, Germany
- EQUAL study
Kitty Jager, Amsterdam, the Netherlands
Bénédicte Stengel, Villejuif, France
- The Berlin Initiative Study - a cohort of older adults
Elke Schaeffner, Berlin, Germany

CME 9.2
Issues in critical appraisal of observational research
- Setting up your study: study questions and study designs
Vianda Stel, Amsterdam, the Netherlands
- Threats to validity of study findings: bias and confounding
Kitty Jager, Amsterdam, the Netherlands
- Prognosis vs aetiology
Friedo Dekker, Leiden, the Netherlands
- Interpretation and presentation of study results
Bob Siegerink, Leiden, the Netherlands


Overview on health care systems in nephrology, dialysis and transplantation in Europe
- Chairs’ introduction
- The Canadian experience of multiple specialty clinics in patients with CKD, cardiovascular disease and diabetes
Adeera Levin, Vancouver, Canada
- Panel debate
Angel de Francisco, Santander, Spain
Maurice Laville, Lyon, France
Charles Tomson, Bristol, UK
Francesco Locatelli, Lecco, Italy
Carl Gustav Elinder, Stockholm, Sweden
Cengiz Utas, Istanbul, Turkey
Christoph Wanner, Würzburg, Germany
Andrzej Wiecek, Katowice, Poland

Ethical concepts and renal replacement treatment
- Ethics and the nephrologist
Richard Trompeter, London, UK
- Conservative management or dialysis in the elderly: a difficult medical, ethical and social choice
Krzysztof Marczewski, Lublin, Poland
- Dialysis in the elderly: ethical aspects of starting or ending dialysis
Drasko Pavlovic, Zagreb, Croatia
- Economic and cultural impacts in dialysis
Frieder Keller, Ulm, Germany



    MAY 19, 20, 21 2013       CONGRESS BODY






S 1.1
Congenital anomalies of kidney and urinary tract (CAKUT)
- Novel genetic aspect of CAKUT (EUCAKUT consortium)
Stefanie Weber, Essen, Germany
- Prenatal diagnosis of renal tract malformations: can it be done and is it worthy?
Adrian S. Woolf, Manchester, UK
- CAKUT in adult age: a covert risk factor for CKD
Guy H. Neild, London, UK


S 1.2
Cystic disease, ciliopathy and mitochondral cytopathies
- Diagnosis, management and prognosis of HNF1B nephropathy from children to adults
Stanislas Faguer, Toulouse, France
- Follow-up of patients with juvenile nephronophthisis after renal transplantation
Rezan Topaloglu, Ankara, Turkey
- Renal involvement in mitochondrial cytopathies
Francesco Emma, Rome, Italy


S 1.3
Challenges in paediatric dialysis
- Haemodialysis in infants with peritoneal dialysis related complications 
Rukshana Shroff, London, UK
- Vascular access: establishment and maintenance
Constantinos J. Stefanidis, Athens, Greece
- Measures to avoid failure of peritoneal dialysis in children
Claus Peter Schmitt, Heidelberg, Germany
- Strategies to prevent PD related infections in paediatric patients
Enrico Verrina, Genoa, Italy


S 1.4
Cardiovascular disease in children with CKD
- The 4C study: a paneuropean paediatric cardiovascular research project supported by ERA-EDTA
Franz Schaefer, Heidelberg, Germany
- Prevention of irreversible cardiovascular disease in CKD children: a diagnosistic challenge
Jaap Groothoff, Amsterdam, the Netherlands
- Ambulatory blood pressure patterns in patients with chronic kidney disease
Empar Lurbe, Barcelona, Spain -
Non invasive cardiovascular monitoring in children with chronic kidney disease and renal transplantation
George S. Reusz, Budapest, Hungary


S 1.5
Early diagnosis of renal diseases in children and young adults
- Early diagnosis of chronic glomerular diseases in children: isolated microscopic haematuria
Asaf Vivante, Tel Aviv, Israel
- Early detection of isolated microscopic haematuria or moderate proteinuria in adolescent and young adults
Alessandro Amore, Turin, Italy
- Diagnosis of renal disease in adults before too late referral
Manuel Praga, Madrid, Spain
- The role of molecular genetics in diagnosing familial haematuria
Constantinos Deltas, Nicosia, Cyprus




- Improvement in the renal prognosis in nephropathic cystinosis
Elena Levtchenko, Leuven, Belgium
- Autoinflammatory diseases in chidren 
Seza Ozen, Ankara, Turkey
- Proposal of new classification (ontology) for rare inherited disorders
speaker to be confirmed
- Etiology and epidemiology of Balkan endemic nephropathy
Nicola Pavlovic, Nis, Serbia



MC 1.1
Nutrition, water and salt in children
- Nutrition in infants with CKD: from basics to practice
Lesley Rees, London, UK
- Interpreting urinary sodium and osmolality in children
Detlef Böckenhauer, London, UK
- Renal calcification in children: origin and outcome
Martin Konrad, Münster, Germany


MC 1.2
Transition of children with renal disease to adult age
- Chronic kidney diseases from childhood to adolescents and from adolescents to adults
Harika Alpay, Istanbul, Turkey
- GFR measurement in children, adolescents and young adults: choose the best formula to obtain coincident values
Licia Peruzzi, Turin, Italy
- Tubular disorders in adults originated in childhood: how to manage a rare condition
Rosa Vargas-Poussou, Paris, France




S 2.1
Transplant tolerance
- Transplant tolerance: lessons from experimental models
Fadi Issa, Oxford, UK
- Protolerogenic effects of Regulatory T cells in renal transplantation
Josep M. Cruzado, Barcelona, Spain
- Regulatory T cells in kidney transplantation: the effect of immunosuppression therapy
Ondrej Viklicky, Prague, Czech Republic
- B cells in transplantation: effectors or regulators?
Sebastiaan Heidt, Leiden, the Netherlands

S 2.2
Immunosuppression: when not enough, when too much
- Immunosuppression in 2013 with the upcoming immunosuppressive drugs: looking for the best cocktail
Rainer Oberbauer, Vienna, Austria
- Patient with a failed graft: how to manage immunosuppression. Should the failed graft be left in place?
Arnaud Del Bello, Toulouse, France
- PTLD after renal transplantation
Josep M. Grinyo, Barcelona, Spain
- mTOR inhibitors lights and shadows
Giuseppe Grandaliano, Foggia, Italy


S 2.3
Antibody mediated graft damage
- The detection and clinical relevance of donor specific antibodies in light of the ERBP guidelines
Frans H.J. Claas, Leiden, the Netherlands
- Is there a role for non-HLA antibodies in allograft rejection?
Daniel Abramowicz, Brussels, Belgium
- Proteasome inhibitor therapy for antibody mediated rejection
speaker to be confirmed
- Induction therapy in sensitized recipients
Georg A. Boehmig, Vienna, Austria

S 2.4  
New perspectives in transplantation therapy
- Therapy with autologous mesenchimal stem cells in transplantation
Ton J. Rabelink, Leiden, the Netherlands
- Interaction between adipose-tissue derived mesenchymal stem cells and regulatory T cells 
Marc H. Dahlke, Regensburg, Germany
- High or low doses of thymoglobulin for induction therapy?
Georges Mourad, Montpellier, France 

S 2.5
Pre-emptive and living kidney transplantation: the way to improve patient outcomes? ESOT-DESCARTES Joint Symposium
- The relationship between dialysis vintage and kidney transplant outcomes
Rainer Oberbauer, Vienna, Austria
- Pre-emptive transplantation with either a deceased or living donor: why, when?
Daniel Abramowicz, Brussels, Belgium
- Outcomes after living kidney donation

Geir Mjøen, Oslo, Norway

 - The work-up of a living donor
Uwe Heemann, Munich, Germany


- Therapeutic potential of mesenchymal stem cell-derived molecules
Vincenzo Cantaluppi, Turin, Italy
- Induction therapy for kidney transplantation after a non-renal transplant
Simin Goral, Philadelphia, USA


MC 2.1
Drugs in transplantation
- Drug level monitoring and adjustment 
Silvio Sandrini, Brescia, Italy
- Early versus late steroid withdrawal
Julio Pascual, Barcelona, Spain
- Steroid minimization /withdrawal in children after renal transplantation
Ryszard Grenda, Warsaw, Poland

MC 2.2
Infection issues in renal transplantation
- CMV and HBV infection in renal transplantation
Chris Dudley, Bristol, UK
- Using kidneys from hepatitis C infected donors?
Josep M. Campistol, Barcelona, Spain
- Polyoma virus infection
Nina Babel, Berlin, Germany





S 3.1
Novel epithelial cell models
- Genetic dissection of ENaC-mediated sodium transport
Edith Hummler, Lausanne, Switzerland
- New epithelial cell models
Claudia Raggi, Montreal, Canada
- Xenopus embryos as animal models for nephrogenesis, kidney diseases and drug discovery
André W. Braendli, Munich, Germany

S 3.2
New insights into the loop of Henle
- Uromodulin biology
Olivier Devuyst, Zurich, Switzerland
- Thick ascending limb and acute ischemic injury
Carsten Willam, Erlangen, Germany
- New transport systems
Pascal Houillier, Paris, France

S 3.3
Fine-tuning of sodium transport in the distal nephron
- Regulation of the thiazide-sensitive NaCl cotransporter
Johannes Loffing, Zurich, Switzerland
- Purinergic signalling
Robert Unwin, London, UK
- Could microRNAS participate to the regulation of ion transport in the nephron?
Juliette Hadchouel, Paris, France

S 3.4
Benefits and risks when pushing renal regeneration
- Renal resident cell reprogramming by microvescicles from endothelial progenitor and stem cells
Giovanni Camussi, Turin, Italy
- Consequences of deregulated glomerular parietal cell activation
Marcus Moeller, Aachen, Germany
- The fostering role of ACE inhibitors
Ariela Benigni, Bergamo, Italy


- CD133  stem cells in renal pathology and repair
Benedetta Bussolati, Turin, Italy
- Is the kidney biopsy currently necessary in the management of lupus nephritis?
Agnes Fogo, Nashville, USA
- Novel mechanisms for Aquaporin trafficking
Robert Fenton, Aarhus, Denmark
- Vasopressin antagonists for ADPKD: a translational story
Vicente Torres, Rochester, USA


MC 3.1
Functional imaging in nephrology
- Nuclear medicine imaging in nephrology
Emmanuel Durand, Strasbourg, France
- MR imaging
Bruno Vogt, Zurich, Switzerland
- Rodent models for functional imaging of the kidney 
Carsten Wagner, Zurich, Switzerland

MC 3.2
An update in hyponatremia
- Hyponatremia in 2013: treat or do not treat (the pitfalls)?
Peter Gross, Dresden, Germany
- Hyponatremia: differential diagnosis
Ewout Hoorn, Rotterdam, the Netherlands
- Hyponatremia: physiology based treatment
Tevfik Ecder, Istanbul, Turkey



S 4.1
New actors in glomerular inflammation
- Macrophages phenotype in renal inflammation
Jeremy Hughes, Edinburgh, UK
- Function of Th17 and Th9 cells in glomerulonephritis
Ulf Panzer, Hamburg, Germany
- Novel molecular mechanisms of renal inflammation 
Hans-Joachim Anders, Munich, Germany
- Homestatic and inflammatory functions of kidney dendritic cells
Christian Kurts, Bonn, Germany

S 4.2
Biological targets for treatment of glomerular diseases
- Anti CD20: emerging treatment strategies of immune-mediated glomerular disease
Fernando Fervenza, Rochester, USA
- Anti-IL-6, anti-IL-1 and belimumab - treatment options for glomerular disease?
Andreas Schwarting, Mainz, Germany
- Heme Oxygenase-1 as a target for TGF-β in kidney disease 
James George, Birmingham, USA
- Epidermal Growth Factor receptor pathway as a potential target for the treatment of renal diseases
Pierre-Louis Tharaux, Paris, France

S 4.3
Membranous nephropathy
- Update in pathogenesis
Pierre Ronco, Paris, France
- Clinical value of anti-PLA2R antibodies in membranous nephropathy
David J. Salant, Boston, USA
- First therapy for membranous nephropathy
Julia Hofstra, Nijmegen, the Netherlands
- Old and new alternative treatments
Claudio Ponticelli, Milan, Italy

S 4.4
IgA nephropathy
- Genetic and epigenetic factors in IgAN

John Feehally, Leicester, UK
- Role of pathology and clinical features in predicting progression of IgA nephropathy: results from the ERA-EDTA research VALIGA
Rosanna Coppo, Turin, Italy
- microRNA analysis in IgAN
Francesco Paolo Schena, Bari, Italy
- New risk factors for progression of IgAN Vladimir Tesar, Prague, Czech Republic

S 4.5
Lupus nephritis and vasculitis
- New classification of lupus nephritis
Ingeborg M. Bajema, Leiden, the Netherlands
- Neutrophil extracellular traps (NETs) - from infection to autoimmunity
Arturo Zychlinsky, Berlin, Germany
- Antiphospholipid syndrome and the kidney
Maria Tektonidou, Athens, Greece
- Balancing efficacy and toxicity of novel treatments for lupus nephritis: EULAR/ERA-EDTA recommendations
Dimitrios T. Boumpas, Athens, Greece

S 4.6
Amyloidosis, light chain nephropathy and myeloma
- News in amyloid treatment
Andrew Davenport, London, UK
- Approach to multiple myeloma patients presenting with renal involvement
Meral Beksac, Ankara, Istanbul
- Recent trials of treatment with rituximab for severe cryoglobulinemic vasculitis
Dario Roccatello, Turin, Italy
- Renal consequences of lymphoproliferative diseases 
Elena Zakharova, Moscow, Russia


- A new biomarker of activity in glomerulonephritis: TWEAK
Alberto Ortiz, Madrid, Spain
- Persistent post-infectious glomerulonephritis: does it exist?
Fernando Fervenza, Rochester, USA
- Interleukin 17 in renal biopsies as risk factor for progression
Sandrine Florquin, Amsterdam, the Netherlands

- New treatment of preeclampsia
Thomas Benzing, Cologne, Germany
- Is there a risk of cardiovascular disease in renal stone formers?
Giovanni Gambaro, Rome, Italy


MC 4.1
The renal consult in the rheumatology unit
- The patient with mono/oligoarthritis and renal abnormalities
Volker Vielhauer, Munich, Germany

- The patient with polyarthritis and renal abnormalities
Mårten Segelmark, Linköping, Sweden
- The patient with systemic autoimmune disease and renal abnormalities
Alan Salama, London, UK


MC 4.2
Diabetic nephropathy: update of an old disease
- News in pathogenesis and in clinical and histological markers
Jesus Egido, Madrid, Spain
- New therapeutic approaches
Per-Henrik Groop, Helsinki, Finland
- Modulation of VEGF by dietary salt
Jens Titze, Nashville, USA

MC 4.3
Glomerular diseases: the new and the renewed
- The frequency of glomerular diseases: a true decrease versus a lack of diagnosis
Loreto Gesualdo, Bari, Italy
- The role of hematuria in the progression of glomerular diseases
Jesus Egido, Madrid, Spain
- Proteinuria as a surrogate marker of renal disease progression: is it a valid target for planning a trial?
Piero Ruggenenti, Bergamo, Italy

MC 4.4 
Circulating and podocitary factors in proteinuria
- The filtration barrier and the podocyte. Why should we care?
Harry Holthöfer, Dublin, Ireland
- Proteinuria: a complex interplay between unique players
Ton J. Rabelink, Leiden, the Netherlands
- Calcium sensing in podocytes
Maria Pia Rastaldi, Milan, Italy  



S 5.1
Kidney in sepsis
- Sepsis in the ICU: cause or consequence of AKI?
Jill Vanmassenhove, Ghent, Belgium -

 Fluid management in septic AKI: liberal vs. restrictive
Achim Joerres, Berlin, Germany
- Non dialysis extracorporeal techniques for treatment of patients with kidney injury in the ICU
Bernd Stegmayr, Umea, Sweden

S 5.2
Biomarkers for AKI
- Acute tubular damage markers and novel recommendations for AKI diagnosis
Michael Haase, Magdeburg, Germany

- Are biomarkers so perfect? An overview
T. Alp Ikizler, Nashville, USA

- One biomarker for the diagnosis of AKI is not enough
Harald Mischak, Hanover, Germany
- Biomarkers versus clinical assessment in AKI
Wim Van Biesen, Ghent, Belgium

S 5.3

AKI: specific causes and conditions
- Crush-AKI in disaster: the ERBP
Mehmet Sukru Sever, Istanbul, Turkey
- Contrast induced nephropathy: the ERBP
Maurice Laville, Lyon, France
- The extracorporeal treatments in poisoning
Jan T. Kielstein, Hanover, Germany


S 5.4
Treatment of AKI
- What trial do we need in conservative treatment of AKI?
Norbert Lameire, Ghent, Belgium
- When to start, when to stop RRT
Claudio Ronco, Vicenza, Italy
- Which timeframe to choose for RRT
Andrew Davenport, London, UK
- How to handle pharmakocinetics with different dialysis modalities?
Jan T. Kielstein, Hanover, Germany


- Nutritional and metabolic support in critically ill patients with AKI
Enrico Fiaccadori, Parma, Italy
- Effects of prolyl-hydroxylase inhibition in kidney disease models
Kai-Uwe Eckardt, Erlangen, Germany


MC 5.1
Challenges in AKI management in ICU
- Anticoagulation strategies for AKI
James Tattersall, Leeds, UK
- Volume management in ICU patients
Ravindra L. Mehta, San Diego, USA
- The difficult AKI case: a quiz with the audience
Steven Van Laecke, Ghent, Belgium

MC 5.2
Diagnosis, prevention and treatment of AKI: the ERBP position statement
- The diagnosis of AKI: the ERBP position statement
Danilo Fliser, Homburg/Saar, Germany
- Epidemiology and consequences of AKI in 2013
Pascal Meier, Sion, Switzerland
- AKI: diagnosis criteria and new therapeutic options 
Laurent Juillard, Lyon, France





S 6.1
Novel risk markers/factors for progression in CKD
- Genetic determinants of kidney function and risk of CKD
Florian Kronenberg, Innsbruck, Austria
- Proteomic markers of progression in diabetic and non-diabetic CKD
Peter Rossing, Gentofte, Denmark
- Acidosis and progression of CKD
Mohammad Magdi Yaqoob, London, UK


S 6.2
Progeria syndrome in CKD/ESRD
- Normal human aging and progeria syndromes
Annachiara De Sandre-Giovannoli, Marseille, France
- Bone loss and vascular calcification progression in CKD: not only a matter of age
Jorge B. Cannata-Andia, Oviedo, Spain
- Accelerated cardiovascular aging in CKD/ESRD
Gérard London, Fleury-Mérogis, France


S 6.3
Sodium in kidney failure patients: new open questions
- Salt as an addictive compound: central mechanisms of salt addiction
Yunus Erdem, Ankara, Turkey
- Low sodium diet in CKD patients: it’s time for action!
Luca De Nicola, Naples, Italy
- Sodium storage in ESRD patients
Jens Titze, Nashville, USA


S 6.4
Phosphate: a novel risk factor for cardiovascular disease and CKD progression
- Phosphate and cardiovascular disease beyond CKD: is phosphate a new cholesterol?
Michel Jadoul, Brussels, Belgium
- Phosphate burden, renal disease progression and the response to nephroprotective treatments
Carmine Zoccali, Reggio Calabria, Italy
- Does phosphate qualify as a cardiovascular risk factor in CKD?
Marcello Tonelli, Edmonton, Canada


S 6.5
Inflammation, oxidative stress and cardiovascular risk in CKD
- The inflamed uremic phenotype - a mediator of premature aging
Peter Stenvinkel, Stockholm, Sweden
- Monocyte heterogeneity and CV risk in CKD
Gunnar H. Heine, Homburg/Saar, Germany
- Improving CKD outcomes by dietary fat manipulation: omega 3 and beyond
Juan-Jesus Carrero-Roig, Stockholm, Sweden
- Oxidative stress and inflammation: a new avenue for the treatment of CKD?
Mustafa Arici, Ankara, Turkey


S 6.6
Management of diabetes in advanced CKD
- Management of diabetes in advanced CKD: the ERBP view
Henk J.G. Bilo, Zwolle, the Netherlands
- RRT Modality Selection in diabetics
Cécile Couchoud, Saint-Denis La Plaine, France
- New-onset diabetes after kidney transplantation

Bo Feldt-Rasmussen, Copenhagen, Denmark




- KDIGO guidelines for lipid management in CKD
Christoph Wanner, Würzburg, Germany
- Renalase in CKD
Jolanta MaƂyszko, Bialystok, Poland




MC 6.1
Lipids in CKD
- LDL-cholesterol and CV risk in CKD: epidemiology vs. clinical trials

David Wheeler, London, UK
- High-density lipoprotein - the myth of the “good cholesterol”
Thimoteus Speer, Homburg/Saar, Germany
- Lipid lowering treatment in diabetics with advanced CKD: the ERBP view
Christiane Drechsler, Würzburg, Germany


MC 6.2
Common CKD problems: new solutions
- Achievements in CKD-MBD guidelines targets
Goce Spasovski, Skopje, F.Y.R. of Macedonia
- New anaemia therapies: translating novel strategies from bench to bedside
Iain Macdougall, London, UK
- CKD treatment and dialysis in the elderly
Marian Klinger, Wroclaw, Poland


MC 6.3
Uric acid and CKD
- Update in uric acid handling
Olivier Bonny, Lausanne, Switzerland
- Genetic epidemiology of hyperuricemia
Gerjan Navis, Groningen, the Netherlands
- The role of uric acid in the progression of CKD
Mehmet Kanbay, Istanbul, Turkey



S 7.1
ERA-EDTA Registry
- Introduction
Christoph Wanner, Würzburg, Germany
- Cardiovascular risk profile in children on RRT
Marjolein Bonthuis, Amsterdam, the Netherlands
- Rare diseases in the ERA-EDTA Registry
Kitty Jager, Amsterdam, the Netherlands
- Vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis)
Vladimir Tesar, Prague, Czech Republic
- Adult Polycystic Kidney Disease
Ron T. Gansevoort, Groningen, the Netherlands
- Dialysis and pregnancies in Europe: the DIAPER study
Marlies Noordzij, Amsterdam, the Netherlands

S 7.2
Hypertension in CKD
- Visit to visit BP variability: a new dimension of blood pressure components in CKD
Francesa Mallamaci, Reggio Calabria, Italy
- 24hs monitoring blood pressure in CKD: why, when and how
Roberto Minutolo, Naples, Italy
- Treatment with blood-pressure-lowering drugs in CKD: thresholds, targets and audit standards
Charles Tomson, Bristol, UK

S 7.3
Forefront in hypertension
- Autoimmune basis of essential hypertension
Bernardo Rodríguez-Iturbe, Maracaibo, Venezuela
- Renal denervation in the treatment of resistant hypertension
Andrzej Wiecek, Katowice, Poland
- New therapeutic approaches: vaccination against the renin angiotensin system 
Duncan J. Campbell, Melbourne, Australia

S 7.4
The endothelium and peripheral nervous system in hypertension
- Vascular adhesion protein (VAP-1) in hypertensive patients in CKD
Michal Mysliwiec, Bialystok, Poland
- Baroreflexes and CV complications in ESRD and dialysis
Andrzej Wiecek, Katowice, Poland
- FGF 23 and endothelial function in CKD and transplant patients
Mahmut Ilker Yilmaz, Ankara, Turkey
- Angiotensin II and endothelial cell permeability
Laszlo Rosivall, Budapest, Hungary

S 7.5
Cardiovascular function in CKD
- Left ventricular dysfunction as a risk factor for death in CKD
Gérard London, Fleury-Mérogis, France
- FGF-23: marker or mediator of left ventricular dysfunction?
Danilo Fliser, Homburg/Saar, Germany
- Pharmacological treatment of LVH and LV dysfunction in CKD and renal transplantation: role of mTOR inhibitors
Ernesto Paoletti, Genoa, Italy
- Effects of phosphate on vascular function - new insights
Ziad Massy, Amiens, France


- Aliskiren effect on bradykinin and tissue kallikrein in the hearth
Duncan J. Campbell, Melbourne, Australia
- Treatment of hyperparathyroidism after the EVOLVE study
Jürgen Floege, Aachen, Germany


MC 7.1
Cardiovascular calcification / CKD-MBD
- Pathogenesis, diagnosis, prevention and treatment of cardiovascular calcifications
Markus Ketteler, Coburg, Germany
- Vitamin D and cardiovascular system
Piergiorgio Messa, Milan, Italy
- Non-calcium containing phosphorus binders: a comparison of efficacy, safety and clinical benefits
Joao M Frazao, Porto, Portugal

MC 7.2
Physical exercise in CKD patients: good for everyone?
- Physical exercise and clinical outcomes in CKD patients: usefulness and safety
Naomi Clyne, Lund, Sweden
- Physical activity and all cause and cardiovascular mortality in renal transplant patients
Stephan J.L. Bakker, Groningen, the Netherlands
- Simple exercise programs applicable at home in dialysis patients
Fabio Manfredini, Ferrara, Italy




S 8.1
Alternative methods of uraemic toxin removal
- Protection of residual renal function
Raymond Vanholder, Ghent, Belgium

- Extracorporeal adsorption
Joachim Jankowski, Berlin, Germany
- Nutritional therapy to change intestinal flora
Bjorn Meijers, Leuven, Belgium
- Metabolism and renal efflux are essential in uraemic toxin clearance
Henricus A. Mutsaers, Nijmegen, the Netherlands

S 8.2
A novel actor: hypo and hyper magnesemia
- Renal magnesium handling; from new transporters to novel concepts
Joost G.J. Hoenderop, Nijmegen, the Netherlands
- Magnesium and vascular status in patients with CKD
Ziad Massy, Amiens, France

- Hypermagnesemia in haemodialysis

Tilman Drueke, Amiens, France

- Hypomagnesemia in transplantation

Steven Van Laecke, Ghent, Belgium

S 8.3
Common dialysis problems: new solutions
- How to assess lung congestion in dialysis patients: LUST an ERA-EDTA supported study
Carmine Zoccali, Reggio Calabria, Italy
- Is HD treatment 3 times per week acceptable as standard therapy?
Stefan Jacobson, Stockholm, Sweden
- Effect of online haemodiafiltration on all-cause mortality and cardiovascular outcomes
Ercan Ok, Izmir, Turkey
- The intradialytic biofeedbacks and the cardiovascular stability in hypotension-prone patients
Antonio Santoro, Bologna, Italy

S 8.4
Peritoneal dialysis news
- Proteomics of PD effluent: can we identify novel biomarkers of membrane injury?
Tim Johnson, Sheffield, UK
- Fluid management in PD: does bioimpedance add value to clinical management?
Simon Davies, Stoke-on-Trent, UK
- Chest ultrasound and hidden lung congestion in peritoneal dialysis patients
Giuseppe Enia, Reggio Calabria, Italy
- PD solutions and clinical outcomes: how will BalANZ and IMPENDIA-EDEN change practice?
Andreas Vychytil, Vienna, Austria

S 8.5
Peritoneal and haemodialysis choices
- Aiding decisions for choosing dialysis modality
Andrew Mooney, Leeds, UK
- Integrating home therapies HHD with PD, including assisted PD
Thierry Lobbedez, Caen, France
- How to manage assisted peritoneal dialysis for the elderly patients
Olof Heimbürger, Stockholm, Sweden
- Cardiovascular prevention by nocturnal haemodialysis
Ali Basci, Izmir, Turkey

S 8.6
International Practices and Improved Dialysis Outcomes: DOPPS
- Key DOPPS findings and related HD practice trends

Hugh Rayner, Birmingham, UK
- CKDOPPS: a study of advanced chronic kidney disease and the initiation of dialysis
Helmut Reichel, Villingen-Schwenningen, Germany
- Mineral and bone disorder therapies and associated outcomes
Raymond Vanholder, Ghent, Belgium
- Clinical practices, support services, and patient-reported outcomes
Stefan Jacobson, Stockholm, Sweden
- Recent trends in anaemia management: impact of payment changes and guidelines
Francesco Locatelli, Lecco, Italy
Panel Discussion



- The vulnerable man - what is the impact of low testosterone levels on the uraemic phenotype?
Peter Stenvinkel, Stockholm, Sweden
- Will the new ESAs change the approach to the treatment of anaemia of patients in dialysis?
Francesco Locatelli, Lecco, Italy


MC 8.1
Home therapies: is success possible?
- Home haemodialysis
Ercan Ok, Izmir, Turkey
- Peritoneal dialysis
Cengiz Utas, Istanbul, Turkey
- Are outcomes in home PD and HD different?
James Heaf, Copenhagen, Denmark

MC 8.2
Peritoneal dialysis: new approaches to common problems
- Prevention strategies for peritoneal-associated infections - the team approach
Andreas Vychytil, Vienna, Austria
- How to establish acute start PD for late presenters
Thierry Lobbedez, Caen, France

MC 8.3
Dialysis complications
- Depression disorders and quality of life in patients undergoing peritoneal dialysis treatment
Kultigin Turkmen, Erzincan, Turkey
- A serious complication in the treatment of peritonitis: ototoxicity
F. Fevzi Ersoy, Antalya, Turkey
- Sudden death in dialysis patients: why? how? when?
Adrian Covic, Iasi, Romania



Joint Symposium Chinese and European Societies of Nephrology.  CSN and ERA-EDTA
- Epidemiology of CKD and dialysis registry in China

Chang Lin Mei, China

- Epidemiology of CKD in Europe

Christoph Wanner, Würzburg, Germany

- IgA Nephropathy in China

Zhi Hong Liu, Nanjing, China

- IgA Nephropathy in Europe

Rosanna Coppo, Turin, Italy

- Acute Kidney Injury
Ravindra L. Mehta, San Diego, USA
- Glomerular diseases
Patrick H. Nachman, Chapel Hill, USA


Developing renal transplantation in the Balkan area
- Bosnia and Herzegovina. Current status and ways to improve transplantation
Halima Resic, Sarajevo, Bosnia and Herzegovina
- Serbia. Dialysis standard and plans for transplantation
Nada Dimkovic, Belgrade, Serbia
- Montenegro. Development of transplantation program
Marina Ratkovic, Podgotica, Montenegro
- Kosovo. How to manage for getting patients transplanted?
Venera Hasangjekaj-Gjuka, Prishtina, Kosovo*
- Albania. Current situation and perspectives for transplantation
Nestor Thereska, Tirana, Albania
- F.Y.R. of Macedonia. Protocol kidney graft biopsies in the clinical practice
Jelka Masin-Spasovska, Skopje, F.Y.R. of Macedonia

Activities for prevention of CKD and optimization of RRT
- Russia. Past and present of RRT
Natalia Tomilina and Boris Bikbov, Moscow, Russia
- Romania. CKD prevention and RRT
Adalbert Schiller, Timisoara, Romania
- Moldova. RRT organization

Petru Cepoida, Chisinau, Moldova

- Lithuania. From RRT to CKD prevention
Inga Bumblyte, Kaunas, Lithuania
- Estonia. Developments of activities for the prevention of CKD
Mai Rosenberg, Tartu, Estonia
- Belarus. Improving RRT
Kirill Komissarov, Minsk, Belarus
- Tunisia. CKD prevention
Fatma Ben Moussa, Tunis, Tunisia
- Algeria. RRT organization
Tahar Rayane, Blida, Algeria
- (title to be decided)
Petru Cepoida, Chisinau, Moldova


- Percutaneous angioplasty of dialysis vascular access: indications/contraindications, patient preparation, procedure steps and precautions, outcomes and complications
- Tunneled dialysis catheter insertion: indications/contraindications, patient preparation, procedure steps and precautions, outcomes and complications
- Peritoneal dialysis catheter insertion: indications/contraindications, patient preparation, procedure steps and precautions, outcomes and complications


Ultrasound in Nephrology

- Introduction
Bernd Krumme, Wiesbaden, Germany
- B-mode Ultrasound of the Kidney
Bernd Krumme, Wiesbaden, Germany
- Diagnostic approach to renal artery stenosis with Doppler sonography
Moreno Bardelli, Trieste, Italy
- Controversial role of resistance indices in renovascular hypertension
Aso Saeed, Gothenburg, Sweden
- Coffee break and “meet the professor”
- Contrast enhanced Ultrasound (CEUS) of the kidney
Konrad Stock, Munich, Germany
- Doppler sonography and AV-fistulae
Jan H. Tordoir, Maastricht, Netherlands
- Final remarks
Bernd Krumme, Germany


Young Nephrologists Platform (YNP)
- Introduction of the Young Nephrologists Platform: aims and possibilities. We are here, join us!
Miklos Zsolt Molnar, Hungary and Andrzej Wiecek, Katowice, Poland
- Result of our first survey: what do the members of ERA-EDTA expect from YNP?
Miklos Zsolt Molnar, Hungary
- Future scientific perspective of young nephrologist in Europe: young scientist point of view
Davide Bolignano, Reggio Calabria, Italy
- Future scientific perspective of young nephrologist in Europe: experienced scientist point of view
Carmine Zoccali, Reggio Calabria, Italy
- Plan and future activities of YNP
Kultigin Turkmen, Erzincan, Turkey
- Closure
Miklos Zsolt Molnar, Hungary



final programme "day by day" - may 18 - 21, 2013